Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an upsized public offering of 31.4 million shares at $17.50 per share, generating approximately $550 million in gross proceeds. The offering is expected to close on July 15, 2026, with proceeds to be used for R&D of product candidates and general corporate purposes.

07/13/2026, 11:10 PM • GlobeNewswire

INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

A class action lawsuit has been filed against Erasca, Inc. alleging that the company and its executives made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims preclinical data was based on improper comparisons to Revolution Medicines and lacked reasonable basis. Following disclosure of a patent infringement letter from Revolution Medicines and adverse Phase I clinical data including a patient death, Erasca's stock fell approximately 59% in total.

07/13/2026, 6:50 AM • GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

Rosen Law Firm is urging investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026 to join a securities class action lawsuit before the August 10, 2026 lead plaintiff deadline. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes.

07/12/2026, 5:53 PM • GlobeNewswire

ERAS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. Investors who purchased ERAS securities between January 14, 2025 and April 26, 2026 can seek lead plaintiff status by August 10, 2026.

07/11/2026, 8:49 AM • GlobeNewswire

Robbins LLP Urges ERAS Stockholders to Contact the Firm for Information About the Class Action Against Erasca, Inc.

A class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025 and April 26, 2026. Shareholders allege that Erasca failed to disclose risks related to patent and trade secret violations regarding its ERAS-0015 drug candidate. The allegations emerged after Revolution Medicines sent a cease-and-desist letter claiming patent infringement and trade secret misappropriation. Following the disclosure on April 27, 2026, Erasca's stock price fell from $21.49 to $19.15 per share.

07/10/2026, 3:07 PM • GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

Rosen Law Firm is soliciting investors who purchased Erasca, Inc. (NASDAQ: ERAS) stock between January 14, 2025 and April 26, 2026 to join a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes. The lead plaintiff deadline is August 10, 2026.

07/09/2026, 7:50 PM • GlobeNewswire

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BitGo Holdings, Inc. (BTGO), Erasca, Inc. (ERAS), and First Solar, Inc. (FSLR) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for three shareholder class action lawsuits. BitGo Holdings faces allegations of false statements regarding digital asset price risks (deadline: August 7, 2026). Erasca is accused of material misstatements about ERAS-0015 between January 2025 and April 2026 (deadline: August 10, 2026). First Solar faces claims of failing to disclose material facts about U.S. tariff policy impacts between February 2025 and February 2026 (deadline: August 24, 2026).

07/07/2026, 3:55 PM • GlobeNewswire

Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSS

Erasca Inc. (ERAS) faces a securities class action lawsuit after its stock plummeted 48% following disclosures of a patient death linked to its experimental drug ERAS-0015 and patent infringement accusations from Revolution Medicines. The lawsuit alleges Erasca misled investors about the drug's safety profile and intellectual property protection through improper comparisons with competing therapies.

07/06/2026, 4:43 PM • GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

A securities class action lawsuit has been filed against Erasca, Inc. for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company and its executives are accused of improperly comparing their drug to a competitor's candidate while failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of August 10, 2026.

07/03/2026, 7:49 PM • GlobeNewswire

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

Erasca, Inc. (NASDAQ: ERAS) stock plunged 48% ($9.25) after the company disclosed a patient death following ERAS-0015 treatment and faced patent infringement accusations from Revolution Medicines. The company allegedly misled investors about the drug's efficacy and intellectual property protection. The disclosure wiped out $2.8 billion in market capitalization, prompting a securities class action lawsuit covering the period from January 14, 2025 to April 26, 2026.

07/03/2026, 2:19 PM • GlobeNewswire

INVESTOR ALERT: Erasca, Inc. (NASDAQ: ERAS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

A class action lawsuit has been filed against Erasca, Inc. for allegedly making false statements about its ERAS-0015 drug candidate. The company allegedly based preclinical data on improper comparisons and failed to disclose patent infringement risks from Revolution Medicines. Following disclosure of a patent assertion letter and Phase I data showing a patient death, Erasca's stock fell 11% then 48%. Investors who purchased stock between January 14, 2025 and April 26, 2026 can seek lead plaintiff status by August 10, 2026.

07/02/2026, 4:55 PM • GlobeNewswire

DEADLINE ALERT for ERAS, NNOX, MSFT, BRCB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Erasca Inc., Nano-X Imaging Ltd., Microsoft Corporation, and Black Rock Coffee Bar Inc. The lawsuits allege that defendants made false or misleading statements regarding their business operations, product performance, and financial prospects. Investors have until mid-August 2026 to file lead plaintiff motions.

07/01/2026, 1:49 PM • GlobeNewswire

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BitGo Holdings, Inc. (BTGO), ADMA Biologics, Inc. (ADMA), and Erasca, Inc. (ERAS) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against BitGo Holdings, ADMA Biologics, and Erasca, Inc. The lawsuits allege that defendants made materially false statements or failed to disclose material facts regarding business risks and practices. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the respective deadlines in August 2026.

07/01/2026, 7:00 AM • GlobeNewswire

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC announces a class action securities lawsuit against Erasca, Inc. for investors who purchased shares between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca and its executives failed to disclose material information, including that preclinical data for ERAS-0015 was based on improper comparisons and placed the company at risk of patent violations. The application deadline to request lead plaintiff status is August 10, 2026.

06/30/2026, 10:51 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding ERAS-0015's preclinical data, which was based on improper comparisons to Revolution Medicines and placed the company at risk of patent and trade secret violations. Investors who purchased Erasca securities between January 14, 2025 and April 26, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.

06/30/2026, 12:00 PM • GlobeNewswire